MedTrace Logo

Serratus Anterior Plane Block Versus Pericapsular Nerve Group Block for Shoulder Surgery

NCT05772533 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-05-30

No results posted yet for this study

Summary

Effective analgesia in arthroscopic shoulder surgery is a major concern and is essential for all aspects of the patient's recovery. The aim of this study is to assess the quality of pain relief in patients who will undergo arthroscopic shoulder surgeries receiving either serratus anterior plane block versus PENG block comparing and evaluating the differences between the two techniques.It is hypothesized that PENG block will be comparable to serratus anterior plane block as a promising effective alternative for analgesia for arthroscopic shoulder surgeries with fewer side effects. It is suggested that the PENG block can be safely applied for analgesia.

Conditions

  • Shoulder Surgery

Interventions

PROCEDURE

Serratus anterior plane block

The latissimus dorsi muscle between the midaxillary line and the posterior axillary line will be located under ultrasound guidance. The needle will be inserted into the plane from top to bottom until the serratus anterior surface, and the injectate will be slowly administered.

PROCEDURE

PENG block

Ultrasound-guided PENG block will be performed under strict aseptic precautions and patient's arm will be placed in external rotation and abducted at 45 degrees. A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the "in plane" technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed Between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • EL-Deeb · Faculty of Medicine, Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-21
Primary Completion
2024-02-15
Completion
2024-03-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05772533 on ClinicalTrials.gov